Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi-long Wu

Showing results (1-10 of 660) with videos related to

Pageof 66
Sort By:
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|April 21, 2007
[Multidisciplinary combination therapy for lung cancer]Yi-long Wu
The Lancet. Oncology|March 31, 2022
Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC - Author's replyYi-Long Wu
The Lancet. Oncology|June 9, 2016
Immunotherapy for small-cell lung cancerYangqiu Li, Yi-Long Wu
Journal of Hematology & Oncology|August 9, 2017
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a reviewShan Su, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 30, 2019
Re-emerging C797S In Trans and Rechallenge of Osimertinib With ErlotinibZhen Wang, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Lung cancer management in the Asia-Pacific region: what's the difference compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer ConferenceYi-long Wu, Qing Zhou
The Lancet. Oncology|May 25, 2019
The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancerYangqiu Li, Yi-Long Wu
Journal of Thoracic Disease|June 29, 2018
Immunotherapy in the Asiatic population: any differences from Caucasian population?Lunxi Peng, Yi-Long Wu
Lung Cancer Management|January 16, 2019
Surgery in oligometastatic NSCLC patients in the targeted therapy eraQi Zhang, Yi-Long Wu
The New England Journal of Medicine|November 8, 2023
Combination Therapy for <i>EGFR</i>-Mutated Lung CancerYi-Long Wu, Qing Zhou
Pageof 66

Showing results (1-10 of 660) with videos related to

Sort By:
Pageof 66
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|April 21, 2007
[Multidisciplinary combination therapy for lung cancer]Yi-long Wu
The Lancet. Oncology|March 31, 2022
Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC - Author's replyYi-Long Wu
The Lancet. Oncology|June 9, 2016
Immunotherapy for small-cell lung cancerYangqiu Li, Yi-Long Wu
Journal of Hematology & Oncology|August 9, 2017
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a reviewShan Su, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 30, 2019
Re-emerging C797S In Trans and Rechallenge of Osimertinib With ErlotinibZhen Wang, Yi-Long Wu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2007
Lung cancer management in the Asia-Pacific region: what's the difference compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer ConferenceYi-long Wu, Qing Zhou
The Lancet. Oncology|May 25, 2019
The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancerYangqiu Li, Yi-Long Wu
Journal of Thoracic Disease|June 29, 2018
Immunotherapy in the Asiatic population: any differences from Caucasian population?Lunxi Peng, Yi-Long Wu
Lung Cancer Management|January 16, 2019
Surgery in oligometastatic NSCLC patients in the targeted therapy eraQi Zhang, Yi-Long Wu
The New England Journal of Medicine|November 8, 2023
Combination Therapy for <i>EGFR</i>-Mutated Lung CancerYi-Long Wu, Qing Zhou
Pageof 66